ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050

Its studies are led by Immunome.

Furthest: phase 1, since Mar 18, 20261 company-led study, 1 open or runningNext primary completion: Dec 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immunome11 open or runningphase 1since Mar 18, 2026Mar 18, 2026Dec 2029phase 1 · NCT07505771

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 18, 2026First study: phase 1 study in Solid MalignanciesFirst studyNCT07505771 · 105 planned · United States

Ahead

  1. Dec 2029Primary completion: phase 1 study in Solid MalignanciesNCT07505771

TargetBeta

FAP →read by rule
“A radioconjugate composed of IM-3050, a small molecule fibroblast activation protein (FAP)-targeting ligand with an albumin-binding domain, a linker, and a chelator, ”NCIt, by rule

Other programs on FAP

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324
Gallium-68Philogenphase 317
Fluorine F 18 FAPI-74rulesofiephase 33
Fluorine F 18 FPyQCPruleBraccophase 21
HRS-6768Jiangsu HengRui Medicinephase 21
Anti-FAP Antibody-drug Conjugate OMTX705ruleoncomatryx-biopharma-s-lphase 12
Gallium Ga 68 NNS309Novartisphase 12
Actinium Ac 225 RTX-2358ruleratio-therapeutics-incphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713ruleEli Lillyphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07505771Solid Malignancies · United States1RecruitingDec 2029105

How it is read

Names in the registry

  • “177Lu-IM-3050”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.